People with CLL face a higher risk of secondary infections. Here’s why it happens, and the prophylactic medications, vaccines ...

Researchers continue to look for better ways to manage CLL, including examining whether newer medications, like the ...

New lymphoma results support development programmeCuris, Inc. (NASDAQ:CRIS) shares climbed 11% on Wednesday after the ...

Patients exposed to vitamin D showed significantly longer treatment-free survival than nonusers, with median durations of 147 vs 82 months.

(NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it will host a webcast ...

Chronic lymphocytic leukemia (CLL) treatment options depend on your diagnosis. In earlier stages, “watchful waiting” may be recommended. More advanced CLL may require a combination of therapies.

Targeted therapies may improve survival in these patients by concurrently managing immune dysregulation and the leukemic clone.

The US Food and Drug Administration (FDA) has granted accelerated approval for lisocabtagene maraleucel (liso-cel) for the treatment of certain adults with relapsed or refractory chronic lymphocytic ...

Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia in adults and is currently incurable. Dr. Brian Koffman, chief medical officer and executive vice president of the CLL ...

Ibrutinib normalizes RBC aggregation in CLL, potentially reducing thrombotic risks by mitigating blood flow complications. Obinutuzumab/venetoclax combination does ...